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Summary
In children with acute myeloid leukaemia (AML), assessment of initial treatment response is an essential prognostic factor; methods more sensitive than morphology are still under evaluation. We report on the measurement of minimal residual disease (MRD), by multicolour flow-cytometry in one centralized laboratory, in 142 children with newly diagnosed AML enrolled in the Associazione Italiana di EmatoOncologia Pediatrica-AML 2002/01 trial. At the end of the first induction course, MRD was <0Á1% in 69, 0Á1-1% in 16 and >1% in 51 patients. The 8-year disease-free survival (DFS) of 125 children in morphological complete remission and with MRD <0Á1%, 0Á1-1% and ≥1% was 73Á1 AE 5Á6%, 37Á8 AE 12Á1% and 34Á1 AE 8Á8%, respectively (P < 0Á01). MRD was also available after the second induction course in 92/142 patients. MRD was ≥0Á1% at the end of the first induction course in 36 patients; 13 reached an MRD <0Á1% after the second one and their DFS was 45Á4 AE 16Á7% vs. 22Á8 AE 8Á9% in patients with persisting MRD ≥0Á1% (P = 0Á037). Multivariate analysis demonstrated that MRD ≥0Á1% after first induction course was, together with a monosomal karyotype, an independent adverse prognostic factor for DFS. Our results show that MRD detected by flow-cytometry after induction therapy predicts outcome in patients with childhood AML and can help stratifying post-remission treatment.
The event-free-survival (EFS) of children with acute myeloid leukaemia (AML) has considerably improved over the past 30 years, currently ranging between 40% and 60% (Rubnitz et al, 2010; Creutzig et al, 2012 Creutzig et al, , 2013 Pession et al, 2013) .
This improvement is mainly due to a combination of better genetic risk stratification of patients, advances in supportive care and optimization in the intensity of treatment, including repeated courses of high-dose cytarabine-based chemotherapy and use of allogeneic haematopoietic stem cell transplantation in first complete remission (CR) in high-risk patients (Gibson et al, 2005 (Gibson et al, , 2011 Pession et al, 2013) .
Despite these encouraging results, relapse remains the main cause of treatment failure in about 30% of childhood AML (Creutzig et al, 2005; Pession et al, 2013) . The majority of relapses stems from the persistence of malignant cells resistant to chemotherapy that cannot be easily detectable through the morphological evaluation of bone marrow smears after induction (Kern et al, 2005; Creutzig et al, 2014) .
During the last 2 decades, new tools to measure the persistence of leukaemia cells (i.e. minimal residual disease, MRD), more sensitive than conventional morphology, have progressively emerged. The methods available include quantitative RNA-based polymerase chain reaction (PCR) analysis of specific gene fusions and flow-cytometry detection of aberrant immune phenotypes on the surface of leukaemia cells (Campana, 2008; Inaba et al, 2012) . Reverse transcription PCR (RT-PCR) for fusion transcripts allows MRD assessment with a sensitivity level of 0Á01-0Á001%, but is applicable only in about 50-60% of paediatric patients harbouring a fusion gene or mutations. There are other limitations to this technique, namely: (i) MRD level can be accurately defined from the amount of PCR products, but the number of transcripts produced by each blast cell is unknown (Campana, 2008) , (ii) evidence regarding the persistence of RUNX1-RUNX1T1 and CBFB-MYH11 fusion transcripts in patients in continuous long-term remission limit the possibility of their use as reliable MRD markers, and (iii) FLT3-internal tandem repeat (ITD) and NPM1 mutations have been previously described as unstable markers for MRD monitoring with possible disappearance between diagnosis and relapse (Coustan-Smith et al, 2003; Coustan-Smith & Campana, 2013) .
Despite these observations, it has recently been shown that assessment of FLT3-ITD transcript levels after the first induction course is feasible and correlated with EFS in childhood AML (Manara et al, 2016) .
By contrast, although the sensitivity of multicolour flow cytometry (MFC) in detecting MRD is lower than that of PCR (0Á1-0Á01%), this approach is much more widely applicable (in more than 90% of cases), supporting the use of MFC as the preferred tool to monitor MRD in AML.
Although some reports unequivocally showed that detection of MRD during treatment predicts final outcome of patients, the prognostic role of MRD in AML and its prospective use in a multicentre study for stratifying patients in different classes of risk to be treated with different therapeutic approaches still remain matters of investigation. The more convincing evidence on the prognostic role of MRD persistence/reappearance derives from patients with acute promyelocytic leukaemia (APL). However, recent papers support the usefulness of MRD also in AML other than APL (Meloni et al, 1997; Grimwade & Tallman, 2011; Sanz & LoCoco, 2011; Coustan-Smith & Campana, 2013; Pigazzi et al, 2015) .
So far, while several retrospective analyses on different cohorts of children with AML demonstrated the prognostic relevance of MRD detection by MFC (Sievers et al, 2003; Langebrake et al, 2006; van der Velden et al, 2010; Loken et al, 2012; Tierens et al, 2016) , only one mono-institutional study from the St Jude group (Rubnitz et al, 2010) documented that MFC-MRD evaluation can be instrumental for prospective stratification of patients and for guiding postremission therapy.
We retrospectively analysed a large group of children with newly diagnosed AML enrolled in the Associazione Italiana di EmatoOncologia Pediatrica (AIEOP)-AML 2002/01 trial with the aim of evaluating the prognostic role of MFC-MRD assessed during induction therapy.
Materials and methods

Patients
From December 2002 to June 2011, 482 paediatric patients with AML were consecutively enrolled in the AIEOP-AML 2002/01 trial for treatment of non-Down syndrome children affected by AML in Italy .
The entry criteria for the AIEOP AML 2002/01 study has been previously reported ; briefly, nonDown syndrome children with newly diagnosed AML other than APL were included in the trial, their age ranging from 0 to 18 years; written informed consent from parents/legal guardians was obtained in accordance to the Declaration of Helsinki. Patients affected by either AML with a previous myelodysplastic phase or with a history of treatment with either cytotoxic agents or steroids during the 2 weeks preceding diagnosis were excluded The study cohort included 67 females (47%) and 75 males (53%) with a median age at diagnosis of 6 years and 10 months (range 0Á1-17Á8 years). Table I details other relevant characteristics of the patients included in the study. Notably, we did not observe any difference in terms of gender, age, white blood cell (WBC) count, French-BritishAmerican (FAB) classification, recurrent genetic abnormalities, risk group stratification between children who were or were not included in this study on MRD monitoring.
All patients had a confirmed diagnosis of de novo AML based on morphological, cytochemical, and immunophenotypic criteria (Basso et al, 2001) .
Cytogenetic and molecular characterization on samples collected at diagnosis was performed for all 142 patients. Monosomal karyotype (MK) was defined as the presence of isolated À7 and À5 using standard banding techniques. Samples were analysed for the presence of t(8;21), inv(16), t (16;16), t(15;17), and t(11q23)/KMT2A (previously termed MLL) and the associated molecular transcripts, namely corebinding factor (CBF)-b (CBFB) abnormalities, PML-RARA, and KMT2A rearrangements (Vardiman et al, 2002; Campo et al, 2011; Pigazzi et al, 2011) . FLT3-ITD was investigated in all patients but one (Manara et al, 2016) .
Morphological CR status and, whenever indicated, diagnosis of relapse were centrally reviewed.
AIEOP AML 2002/01-02 study for treatment All patients were stratified as either "standard risk" (SR) or "high risk" (HR), according to cytogenetic criteria and response to first induction course. Children with anomalies of CBFB as the sole cytogenetic abnormality and in morphological CR after the first induction course were assigned to SR treatment; all other children were allocated to the HR block. Details on treatment protocol have been extensively reported elsewhere and summarized in Figure S1 .
Immunophenotypic studies at diagnosis
Immunophenotyping studies were performed at diagnosis on erythrocyte-lysed whole BM samples by MFC, using a direct immunofluorescence technique with 5-colour combinations of monoclonal antibodies (MoAbs) ( Table SI) .
Bone marrow samples, delivered at ambient temperature, were processed within 24 h of collection, and analyses were performed as previously described (Basso et al, 2001) .
Briefly, in each analysis, 0Á5 9 10 6 cells were incubated at room temperature for 15 min in the dark with the appropriate combinations of MoAbs directly conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE), tandem PETexas red (ECD), tandem PE-cyanin 5 (PeCy5) and tandem PE-cyanin 7 (PeCy7). Samples were subsequently lysed using 3 ml of NH 4 Cl, then washed in phosphate-buffered saline (PBS) and re-suspended in 0Á5 ml of PBS. Intracellular staining for myeloperoxidase and lactoferrin (MPO and LACTO) was performed with a two-step fixation and permeabilization method using a commercial kit (Valter Occhiena-Caltag Laboratories -Fix&Perm ™ , San Francisco, CA) according to manufacturer's instructions. The following MoAbs were used: CD4-FITC, CD8-PE, CD41-FITC, CD15-FITC, CD66b-FITC, CD64-FITC, CD2-FITC, CD80-FITC, CD71-FITC, CD61-PE, CD123-PE, CD38-Pe-Cy5, CD34-Pe-Cy5, CD34-Pe-Cy7, HLA-DR-Pe-Cy7 (Becton Dickinson Franklin Lakes, New Jersey), CD7-FITC, CD7-Pe-Cy5, CD52-FITC, CD13-FITC, CD65-FITC, CD13-PE, CD44-PE, CD15-PE, LACTO-PE (Invitrogen, Carlsbad, CA, USA), CD45-ECD, CD33-Pe-Cy5, CD25-Pe-Cy5, CD16-PeCy5, CD20-Pe-Cy5, CD83-Pe-Cy5, CD3-Pe-Cy7, 7.1-PE, CD19-Pe-Cy7, CD66c-FITC, CD10-FITC, CD116-PE, CD14-PE, CD11b-PE, CD11a-PE, CD117-PE, CD56-PE, CD135-PE, CD86-PE, CD114-PE (Beckman Coulter, Indianapolis, IN, USA), MPO-FITC (Dako, Santa Clara, CA, USA), CD133-PE (Miltenyi Biotec, Bergisch Gladbach, Germany). Cell acquisition was performed using an FC 500 flow-cytometer (Beckman Coulter), equipped with a 488 nm blue laser and a 633 nm red laser. The software used for analysis was CXP Software (Beckman Coulter).
For the immunophenotypic diagnosis 30 000 events were considered for each sample-MoAb combination.
Instrument set-up was routinely optimized by analysing Flow-Check M Fluorospheres (Beckman Coulter) or similar products according to manufacturer's recommendations as previously reported (Dworzak et al, 2008) , and normal peripheral blood T lymphocytes stained with the anti-CD4-FITC/ CD8-PE/CD45-ECD/CD7-Pe-Cy5/CD3-Pe-Cy7 five-colour combination, as previously reported (Dworzak et al, 2008) .
Efficiency of erythrocyte lysis was monitored by an extra staining combination of SYTO16 (Molecular Probes, Leiden, The Netherlands), a live-cell-permeant nucleated-cell dye, and 7AAD, to identify dead cells in each sample (Beckman Coulter-Immunotech, Miami, FL, USA).
Leukaemia cells were identified using an immunological gate based on CD45 expression, associated with a physical parameter (Side Scatter [SSC]) (Borowitz et al, 1993; Basso et al, 2001 ).
Flow cytometric evaluation of minimal residual disease
Bone marrow aspirates were collected at time of haematological recovery after the first induction course in 142 patients; 94 of them were also analysed at time of haematological recovery after the second induction course ( Figure S1 ).
Specimens were processed with the same procedure employed at diagnosis, but using 10 6 cells for each tube.
MRD was assessed by 5-colour MFC acquiring at least 500 000 events for each tube. Minimal residual disease monitoring by MFC relies on the expression of specific leukaemia-associated immunophenotypes (LAIPs), defined as the presence of an aberrant combination of antigens and/or flow-cytometry physical abnormalities, absent or very infrequent in normal or regenerating BM (Wood, 2007) . This approach allows reaching a sensitivity of MRD detection of at least 0Á1% (i.e. 1 cell in 1000), this threshold being consistent with that reported by Rubnitz et al (2010) and capable of discriminating between MRD-positive and MRD-negative samples.
We defined patient-specific LAIP at diagnosis in order to monitor MRD during follow-up. We used 1-3 combinations of antigens per patient to minimize false-negative results in case of phenotypic switches at relapse (Baer et al, 2001; Voskova et al, 2004) ; in particular, we used 1 combination for 11 (7Á7%), 2 for 95 (66Á9%) and 3 for 36 (25Á4%) patients, respectively.
Each combination included the common antigen backbone CD45 (ECD)/CD33(Pecy5)/CD34(Pecy7) to simultaneously analyse myeloid and immature populations. In addition to the common antigen backbone, every combination included two specific antigens defined for each patient at diagnosis. SYTO16 combination (SYTO16/GLY-A/CD45/7AAD) was used to assess nucleated cells (SYTO16+) and to identify dead cells (7AAD+) in each sample.
The following monoclonal antibodies were the most used in 5-colour combinations for MRD detection: CD13-FITC, CD117-PE, CD7-PE, CD56-PE, CD7.1-PE, CD15-FITC, CD64-FITC, CD11a-PE, CD11b-PE, CD14-PE (see also Table SII for details).
The first gate to detect MRD was based on the LAIP identified for each patient at diagnosis. A cluster of at least 50 events (among the 500 000 acquired events) was considered to be able to discriminate leukaemia cells from normal ones.
A secondary gate was performed on patient-specific CD45 versus log SSC properties. The final back-gate, based on physical-parameters ([SSC]/Forward Scatter [FSC]), was applied.
Residual leukaemia cells were quantified as a percentage of blasts among nucleated cells.
Statistical analysis
Overall survival (OS) was calculated from date of diagnosis to time of death, due to any cause, or time of last contact.
Event-free-survival was calculated from the date of diagnosis to last follow-up or first event (failure to achieve CR, relapse, secondary malignancy or death due to any cause, whichever occurred first).
Disease-free survival (DFS) was calculated from the date of first CR to last follow-up or first event (relapse, secondary malignancy or death due to any cause, whichever occurred first).
Probabilities of OS, EFS, and DFS were estimated using the Kaplan-Meier method; differences between groups were evaluated through the log-rank test. The cumulative incidence of relapse (CIR) was estimated considering death in remission as the competing event. Gray's test (Gray, 1988) was used to assess, in univariate analyses, differences between cumulative incidences.
In univariable analysis, the following variables that potentially influence the probability of OS were considered: age, gender, FAB subtype, WBC count, risk group stratification, MRD after the first induction course including idarubicin, cytarabine and etoposide (ICE1-MRD), MRD after the second induction course including idarubicin, cytarabine and etoposide (ICE2-MRD), complex karyotype, MK, FLT3-ITD. All variables having a P value <0Á05 in univariable analysis were included in a multivariable analysis on EFS, using the Cox proportional regression model.
Computations were performed using SAS (SAS Institute Inc, Cary, NC, USA).
Results
Of the 142 patients included in this study, 125 achieved morphological CR after the first induction course, which was also maintained after the second induction course, while 11 who were not in morphological CR after the first induction course obtained a first CR after the second induction course. The remaining 6 patients obtained only a partial response after both the first and second induction course and were, thus, considered as non-responders to induction.
We observed concordant results by MFC in 14 out of the 17 patients reported not to be in morphological CR after the first induction course. MFC showed discordant results in 3 patients with >5% morphologically evident leukaemia blasts: 2 were MFC-MRD negative (one received a haematopoietic stem cell transplantation and is still in CR at 6 years from diagnosis and the other one died due to sepsis after the second induction course) and 1 was MFC-MRD positive at a level of 2% (this child subsequently died from disease progression, see also Table SIII ). The discrepancy between morphology and MFC in these 3 cases could be interpreted in light of the difficult morphological evaluation in case of marrow regeneration following induction therapy.
The large majority of patients were assigned to the HR group (113 of 142, 79Á6%), whereas 29 of 142 (20Á4%) were assigned to the SR group (see above for details) .
With a median follow-up of 63 months (range 6-10), the 8-year probability of OS, EFS and DFS for of the 142 children included in this study were 67% (standard error [SE] 4%), 48% (SE 5%) and 55% (SE 5%), respectively (Figure S2) , not significantly different from those recorded for the whole population of patients treated in the AIEOP AML 2002/01 trial . In fact, in the whole population of 482 patients included in the AIEOP AML 2002/01 trial, the 8-year OS, EFS and DFS were 68%, 55%, and 63%, respectively. Likewise, the outcome of the SR and HR subgroups of patients who were or were not included in this study on MFC-MRD was comparable (data not shown).
Minimal residual disease levels at time of haematological recovery after the first (ICE1) and the second (ICE2) induction course in the whole cohort of 142 patients (irrespective of whether they did or did not achieve morphological CR), in relapsed patients and in non-relapsed patients are shown in Fig 1A-C. After the end of the first induction course, MRD level was <0Á1% in 69 patients, ≥0Á1% and <1% in 16 patients and ≥1% in 51 patients. MRD levels measured after the second induction course in the 94 patients with samples available for MFC-MRD analysis were <0Á1% in 57 patients, ≥0Á1% and <1% in 8 patients and ≥1% in 20 patients, respectively.
Six of the 142 BM specimens analysed by MFC at the end of ICE1 and nine of the 94 samples analysed at the end of ICE2 were not evaluable because of high cell mortality (defined as 7AAD+ >30%).
The correlation between DFS probability and levels of MFC-MRD was assessed in the 125 patients in morphological CR after the first induction course; DFS was significantly different when using the MRD cut-off level of 0Á1%. As shown in Fig 2A, according to MRD levels after ICE1, patients were stratified into three MRD-based groups (MRD <0Á1%; MRD 0Á1-1%; MRD ≥1%) with significantly different 8-year DFS probabilities, namely 73Á1 AE 5Á6%, 37Á8 AE 12Á1% and 34Á1 AE 8Á8% respectively (P < 0Á01).
Given that patients with MRD ≥1% or MRD 0Á1-1% at the end of ICE1 had similar DFS, we considered to group these children together: patients with MRD ≥0Á1% had a DFS of 35Á2 AE 7Á2% at 8 years, whereas those with MRD <0Á1% had a DFS of 73Á1 AE 5Á6% (P < 0Á01) (Fig 2B) . The 8-year probability of OS in patients with MRD <0Á1% or ≥0Á1% at the end of the first induction course was 82Á2% and 51Á6%, respectively (P = 0Á0005) ( Figure S2D ). The cumulative incidence of relapse in patients with MRD <0Á1% or ≥0Á1% at the end of the first induction course was 23Á5% and 62Á8%, respectively (P = 0Á0005) (Fig 2C) .
Similarly, we assessed the correlation between levels of MFC-MRD at the end of ICE2 and DFS. As shown in Fig 3A and B, patients were stratified into three MRD-based groups (MRD <0Á1%; MRD 0Á1-1%; MRD ≥1%) with significantly different 8-year DFS probabilities, namely 68Á4 AE 7Á9%, 20 AE 1Á2% and 23Á8 AE 1Á2% respectively (P < 0Á01). We also combined the results into two MRD-based groups: patients with MRD ≥0Á1% had a DFS of 21Á9 AE 9Á4% at 8 years, whereas those with MRD <0Á1% had a DFS of 68Á4 AE 7Á9% at 8 years (P < 0Á01). The 8-year probability of OS in patients with MRD <0Á1% or ≥0Á1% at the end of the second induction course was 77Á1% and 55Á5%, respectively (P = 0Á0275) ( Figure S2E ).
The cumulative incidence of relapse in patients with MRD <0Á1% or ≥0Á1% at the end of the second induction course was 31Á6% and 73Á9%, respectively (P = 0Á00078) (Fig 3C) .
Moreover, we restricted the analysis to the 36 (38Á3%) patients with MRD level ≥0Á1% at the end of ICE1 and with available MRD ICE2 data, assessing the DFS at 8 years for different levels of MFC-MRD obtained at the end of the second induction course. The 8-year DFS was 45Á4 AE 16Á7% for the 13 patients who reached a MRD level<0Á1% at the end of ICE2, 20 AE 12Á6% for the 10 patients with a MRD between 0Á1% and 1% and 25 AE 12Á5% for the 13 patients whose MRD levels were ≥1% (P = 0Á10). We combined these results into two MRD-based groups: DFS was 45Á4 AE 16Á7% for patients with MRD <0Á1% and 22Á8 AE 8Á9% for patients with MRD ≥0Á1% at the end of ICE2 (P = 0Á037). (Fig 4A and B) .
Considering the low number of SR patients (n = 29) included in the study and the comparable EFS between SR and HR who were or were not included in this study (Pession et al, 2013), we did not perform DFS analysis in individual subgroups.
The univariate analysis of prognostic factors potentially influencing patients' DFS is shown in Table SIV ; MFC-MRD after ICE1 and ICE2, as well as MK (defined as presence of isolated À7 and À5) were the only variables statistically influencing outcome in the whole cohort of 142 patients. Multivariate analysis identified ICE1-MRD ≥0Á1% and MK as independent adverse prognostic factors for DFS (P values, 0Á01 and 0Á02, respectively) (see also 
Discussion
The aim of our study was to verify the prognostic role of MFC-MRD evaluated at the end of each of the 2 courses of induction therapy in a large group of Italian paediatric patients with newly diagnosed AML. In view of the MRD levels after the second course of chemotherapy, patients were stratified into (A) three MRD groups (MRD ≤0Á1%; MRD 0Á1-1%; MRD ≥1%) and into (B) two MRD groups (MRD ≤0Á1%; MRD ≥0Á1%). Cumulative incidence of relapse at 8 years in patients with MRD <0Á1% or ≥0Á1% at the end of the second induction course. CIR, cumulative incidence of relapse; CR, complete remission; DFS, disease-free survival; MFC, multi-colour flow cytometry; MRD, minimal residual disease; SE, standard error. DFS by MFC-MRD status at the end of induction course 1. According to MRD levels, patients were stratified into (A) three MRD groups (MRD <0Á1%; MRD 0Á1-1%; MRD ≥1%) and (B) into two MRD groups (MRD <0Á1%; MRD ≥0Á1%). Cumulative incidence of relapse at 8 years in patients with MRD <0Á1% or ≥0Á1% at the end of the first induction course (C). CIR, cumulative incidence of relapse; CR, complete remission; DFS, disease-free survival; MFC, multi-colour flow cytometry; MRD, minimal residual disease; SE, standard error.
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Although achievement of CR is a prerequisite for a definitive cure in AML, morphological assessment of BM has the intrinsic limitations of being subjective and of lacking accurate sensitivity, because residual leukaemia cells might be present below the threshold of sensitivity of light microscopy (Campana & Pui, 1995; Venditti et al, 2000; Campana, 2003) . The clinical importance of MRD detected by either MFC or molecular methods has been proven mainly in retrospective studies (Campana & Pui, 1995; Coustan-Smith et al, 2003; Langebrake et al, 2006; van der Velden et al, 2010; Loken et al, 2012; Tierens et al, 2016) . Risk-directed therapy based on MRD assessment may contribute to improve the outcome of patients with AML, as shown in a prospective study conducted at St Jude Children's Research Hospital, where MRD ≥1% after the first induction therapy was the only independent variable predicting EFS and OS in a multivariate analysis (Rubnitz et al, 2010) . Moreover, in one adult study, retrospectively defined cut-off points have been validated in a prospective cohort (Terwijn et al, 2013) .
Minimal residual disease detection by MFC may represent the best tool to tailor treatment according to cell sensitivity to cytotoxic drugs, because it is applicable in the vast majority of patients, as also confirmed in this study, and appears to predict patient outcome in different studies addressing this issue in both paediatric and adult AML (San Miguel et al, 1997 Venditti et al, 2002 Venditti et al, , 2003 Kern et al, 2004a,b; Rubnitz et al, 2010; van der Velden et al, 2010; Loken et al, 2012; Coustan-Smith & Campana, 2013; Terwijn et al, 2013) . However, cut-off values for MRD and optimal time points during treatment for discriminating patients with different prognosis are still a matter of debate.
Our data indicate that an MRD value ≥0Á1% at the end of the first induction course has a relevant power to predict patient outcome. Early achievement of MRD negativity correlated with better outcome, this finding supporting the role of MFC MRD as a strategy that permits accurate post-remission evaluation and risk stratification also in AML. Our results provide support to those reported by other international cooperative groups in different cohorts of children treated with different strategies and using different cut-off values for MRD (Campana & Pui, 1995; Rubnitz et al, 2010; van der Velden et al, 2010) .
In our study, at the end of the first induction course, 49% of patients had detectable MRD (defined as ≥0Á1% blasts). The proportion of poor responders is lower than that reported in the Dutch Childhood Oncology Group MRC cohort (66%) (van der Velden et al, 2010) , slightly higher than that of the studies published by the St Jude Children's Research Hospital (36Á6% using a 0Á1% cut-off level) (Rubnitz et al, 2010) and the Children's Oncology Group (31%, positivity defined at a lower level, 0Á02%) (Loken et al, 2012) and comparable to that recently reported by the Nordic Society for Paediatric Haematology and Oncology (47% using a 0Á1% cut-off level in a multicentre laboratory approach) (Tierens et al, 2016) . These discrepancies are probably attributable to the different induction therapies and, possibly, to the different cut-off levels employed in these studies.
Considering the prognostic value of persistent disease after initial treatment and the number of patients still positive by MFC-MRD at the end of the first induction course of different treatment protocols, future randomized studies should DFS by MFC-MRD status at the end of induction 2, in patients with MRD ≥0Á1% at the end of induction 1. According to MRD levels after the second course of chemotherapy, patients were stratified into three MRD groups (MRD ≤0Á1%; MRD 0Á1-1%; MRD ≥1%) (A) or into two MRD groups (MRD ≤0Á1%; MRD ≥0Á1%) (B). CR, complete remission; DFS, disease-free survival; MFC, multi-colour flow cytometry; MRD, minimal residual disease; SE, standard error.
also aim to identify the induction course that could better reduce MRD. Our data suggest that measurements of treatment response by MFC are widely applicable and provide strong prognostic information early, complementing the conventional risk group stratification based on genetic/molecular features. The outcome of SR patients in the AML 2002/01-02 trial was inferior to that reported by other groups (Gibson et al, 2005; Tsukimoto et al, 2009; von Neuhoff et al, 2010; Rubnitz et al, 2010; Creutzig et al, 2011 Creutzig et al, , 2012 . MFC-MRD assessment can help to identify those SR patients that may be considered for more aggressive treatments. The new ongoing AIEOP study, AML 2013, uses MRD-MFC to better define response to treatment and guides treatment intensification with the aim of improving patients' outcome; in particular, patients with either CBFB anomalies or NPM1 mutations and MRD levels >0Á1% will not be treated according to the SR protocol.
We also investigated the modification of MRD levels after the second induction course in children still positive after the first induction course. DFS was significantly different (P = 0Á037) when considering only two groups of patients, those with MRD <0Á1% and ≥0Á1% at the end of the induction course 2. Children with MRD <0Á1% at the end of second induction therapy, but who had a positive MRD after the initial treatment, remain at higher risk of relapse and have poorer outcomes as compared to those with a negative MRD after the first induction course; these findings, similarly to those reported by Loken et al (2012) , suggest that further effective intervention beyond clearance of MRD is required for improving patient outcome.
As mentioned above, in multivariable analysis, only the presence of MRD (≥0Á1%) at the end of the first induction course and MK remained independent prognostic factors.
Among the 142 children recruited in this study, relapse occurred in 55 patients; 15 of them were MRD negative at the end of the first induction course, confirming other studies that described AML recurrence in about 20% of patients MRD negative after remission induction therapy (Campana & Pui, 1995; Rubnitz et al, 2010; van der Velden et al, 2010; Karol et al, 2015) . The occurrence of relapse despite response to induction therapy could be related to genetic features. This suggests that genetics aberrancies may influence relapse more than MRD in some cases (Pigazzi et al, 2011; Karol et al, 2015) . This hypothesis is supported by the observation that, in our cohort, the majority of patients with good MRD response to induction therapy who subsequently relapsed had known poor genetic risk factors, such as FLT3-ITD, CBFBT3 -GLIS2 fusion transcripts, complex karyotype, and t (8;21) associated with KIT mutation (Meshinchi et al, 2001 (Meshinchi et al, , 2006 Gruber et al, 2012; Masetti et al, 2013) . Failure to detect residual leukaemia cells by MFC due to immunophenotypic shifts, the limits of manual gating strategies to analyse multidimensional data and the failure to identify all subclones or leukaemic cell subsets with self-renewal capacity may also contribute to explain disease recurrence in MFC-MRD negative patients. Indeed, it has been shown that AML comprises a salad bowl of distinct subclones characterized by the presence of genetically-determined recurrent mutations, and that relapse could be due to a single AML subclone, which is not necessarily the same as that identified at diagnosis (Duque-Afonso & Cleary, 2014) .
Advances in flow-cytometry integrated with molecular biology are needed to direct MRD analysis not only to the bulk population of cells, but also on minor subclones of this heterogeneous disease. New technologies are being developed to pursue single-cell analysis, including flow cytometric identification of gene-specific mRNA (Porichis et al, 2014) , digital PCR and Next Generation Sequencing.
MFC-MRD is in continuous development, with the integration of new leukaemia-specific markers (Coustan-Smith & Campana, 2013) and the number of fluorochromes will ensure further improvements of the efficiency of this approach. MRD-MFC detection needs extensive expertise, found only in large laboratories that analyse a huge number of leukaemia and regenerating BM samples (CoustanSmith & Campana, 2013) . Moreover, centralizing samples and data exchange among reference expert laboratories could improve the standardization of methods and the ability to detect residual leukaemic cells, as already demonstrated in ALL (Dworzak et al, 2008) . In this context, in Europe, considerable efforts are being made by at least two international collaborative groups with regard to standardization of sample preparation and analysis. The outcome of paediatric AML needs continuous collaborative efforts to cure the majority of children with AML (Zwaan et al, 2015) .
Altogether, our results provide further support for the use of MRD for risk assignment in childhood AML. MRD evaluation can be complemented by presenting features, such as genetic abnormalities or high WBC at diagnosis, with the goals of refining risk stratification and, thus, improving the outcome of children with newly diagnosed AML.
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Additional Supporting Information may be found in the online version of this article: Fig S1. Schematic representation of the induction and consolidation courses employed for treating patients enrolled in the AIEOP AML 2002/01 trial. ICE = idarubicin, cytarabine, etoposide; AVE = high-dose cytarabine (HD-AraC) and etoposide; HAM = HD-AraC and mitoxantrone; MFD, matched family donor; HSCT, hematopoietic stem cell transplantation; SR, standard risk; HR, high risk; IND, induction; CONS, consolidation; BM, bone marrow at diagnosis; BM/MRD I, bone marrow first induction course; BM/ MRD II, bone marrow after second induction course. (1). Fig S2. Eight-year probability of OS (A), EFS (B) and DFS (C) for the whole cohort of children enrolled in our MFCstudy. Eight-year probability of OS according to MRD <0Á1% or ≥0Á1% at the end of the 1st (D) and the 2nd (E) induction course. Table SI . Antibody panel used for immune-phenotype studies at diagnosis. Table SII . The most common five-color combinations used to assess MRD after first and second induction courses. Table SIII . Comparison between MRD-MFC results and morphological evaluation of bone marrow smears at the end of ICE1. Table SIV . Univariable analysis of prognostic factors.
